12:00 AM
 | 
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Opsumit macitentan regulatory update

Actelion said EMA accepted for review an MAA for Opsumit macitentan to treat pulmonary arterial hypertension. In October, the company...

Read the full 77 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >